ArticleAnnals of translational medicine2022

Overall survival benefits provided by lenalidomide maintenance after chimeric antigen receptor T cell therapy in patients with refractory/relapsed diffuse large B-cell lymphoma.

Nana Ping et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.